

ASX Announcement

3 September 2026

QUERIES REGARDING BDX'S AND ASSOCIATES' SHAREHOLDING IN GSS AND RECEIPT OF SECTION 249D NOTICE FROM BDX

- Genetic Signatures Limited (ASX: GSS) has requested BCAL Diagnostics Ltd (ASX: BDX) (**BDX**) to clarify the details of its shareholdings and associates in GSS.
- BDX has served a section 249D notice on GSS calling for the removal of GSS's current Chair, Mike Aicher, and appointment of John Robert Melki and Susan Margaret Forrester as directors of the Company.

Genetic Signatures Limited (ASX: GSS) (GSS or the Company) refers to the Form 604, Notice of change of interests of substantial holder (**Form 604**), lodged by BDX on 26 August 2026, notifying the Company of BDX's purported acquisition of 18,750,000 shares in the Company, resulting in an increase in its relevant interest from 10.2% to 18.46%.

GSS has undertaken a review of its share register, and notes that there has been no recorded increase in BDX's shareholding in the Company. Instead, GSS's share register, as at the date of this announcement, indicates that the same number of shares purportedly acquired by BDX are held by an entity named Lawn Views Pty Ltd <Angela Williams Family A/C> (**Lawn Views**). Lawn Views' address, as recorded on GSS's share register, is at Level 29, 55 Collins Street, which is also the registered office of Kidder Williams Limited.

Based on its review of the ASIC companies' register, the Company understands that Lawn Views' sole director and shareholder is Angela Kate Williams.

GSS notes that in BDX's ASX announcement of 26 August 2026, BDX states that "*BCAL has acquired 18.75 million Genetic Signatures shares for \$1.5 million, at 8.0 cents per share for cash.*"

GSS has written to BDX asking it to clarify whether:

- BDX owns the 18,750,000 shares that were the subject of its 26 August 2026 announcement;
- any of BDX's associates own shares in GSS; and
- for the purposes of section 671B(3)(d)(iii) of the *Corporations Act 2001* (Cth) (**Corporations Act**), any relevant agreement exists between BDX and Lawn Views or any of its associates.

GSS also advises in accordance with ASX Listing Rule 3.17A, that it has received a request from BDX pursuant to section 249D of the Corporations Act for the directors of GSS to call and arrange a general meeting of shareholders of GSS for the purposes of considering three proposed resolutions, of which:

- one resolution is proposed for the removal of Michael Aicher as director of the Company (**Proposed Removal**); and
- two resolutions are proposed for the appointment of Susan Margaret Forrester and John Robert Melki as directors of the Company (**Proposed Appointments**).

GSS is considering the section 249D notice and, if it considers the notice to be valid, GSS will comply with its relevant obligations under the Corporations Act and will undertake the necessary steps to convene a general meeting.

– END –

Announcement authorised by Genetic Signatures Limited's Board of Directors.

For further information, see our website (www.geneticsignatures.com) or contact us:

Mike Aicher

Chair, Genetic Signatures Limited
mike.aicher@geneticsignatures.com
T: +61 (0)2 9870 7580

Maria Halasz

CEO, Genetic Signatures Limited
maria.halasz@geneticsignatures.com
T: +61 (0)2 9870 7580

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.